Back to top

Names Under Consideration

Back to top

USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.

Visit United States Adopted Names FAQ to learn more. 

Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected].

In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following names for the drugs described are "under consideration" by the USAN Council:

March, 2017

abervitinib: treatment of Diabetic macular edema, Chorodial Neovascularization, Posterior vitreous detachment

avapasem manganese: treatment of mucositis

avelintinib: treatment of Diabetic macular edema, Chorodial Neovascularization, Posterior vitreous detachment

orliteganib: treatment of Diabetic macular edema, Chorodial Neovascularization, Posterior vitreous detachment

risuteganib: treatment of Diabetic macular edema, Chorodial Neovascularization, Posterior vitreous detachment

samitolisib: treatment of cancer

saritolisib: treatment of cancer

suritolisib: treatment of cancer

February, 2017

burtomab: treatment of pediatric cancers

lisocabtagene maralentileucel: antineoplastic, autologous genetically modified cellular therapy

reluperidone: treatment of schizophrenia

solorinab: treatment of pain

January 2017

aprolesel: treatment of hematologic malignancies

anabasum: treatment of cystic fibrosis

bomanezumab pegol: treatment of Alzheimer’s Disease

clatimagene carmaleucel: treatment of potential transplant rejection

contesolid acefosamil: antibiotic

contezolid: antibiotic

covolizumab: treatment of cancer, checkpoint inhibitor

donislecel: cellular therapy treatment for diabetes

dovocizumab: treatment of hypercholesterolemia

ermekumab: cachexia, oncology, vascular disease, diabetes, psoriasis, acne, etc.

esimipasem manganese: treatment of mucositis

fidanacogene elaparvovec: treatment of hemophilia B

filoteganib: treatment of Diabetic macular edema, Chorodial Neovascularization, Posterior vitreous detachment

hydromorphisal: treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase gene

iblamterene: treatment of cystic fibrosis and primary ciliary dyskinesia

marstacumab: preventing bleeding episodes in adults and children with hemophilia

nirsevumab: treatment of respiratory syncytial virus  

odatilumab: treatment of osteoarthritis and rheumatoid arthritis

ostarlizumab: treatment of cancer, checkpoint inhibitor

sedotristat: treatment of pulmonary arterial hypertension

sontimesel: treatment of hematologic malignancies

subitolisib: treatment of cancer

tofersen: treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase gene

trigriluzole: treatment of spinocerebellar ataxia

Email this page